Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

• ClinicalTrials.gov Identifier: NCT02576496
• Recruitment Status: Recruiting
• First Posted: October 15, 2015
• Last Update Posted: March 9, 2023
• Sponsor: Mundipharma Research Limited
• Information provided by (Responsible Party): Mundipharma Research Limited

Tracking Information

• First Submitted Date: October 12, 2015
• First Posted Date: October 15, 2015
• Last Update Posted Date: March 9, 2023
• Study Start Date: March 2016
• Estimated Primary Completion Date: May 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 10, 2020)

• Overall response rate [ Time Frame: 10-20 months from beginning of stage 2 ]
  Determine overall response rate
• Clinical benefit rate by cohort [ Time Frame: 10-20 months from beginning of stage 2 ]
  Determine clinical benefit rate by cohort
• Safety of selected doses in expanded population [ Time Frame: 36 months from beginning stage 2 ]
  Number of participants with treatment-related adverse events as assessed by CTCAE V4.03

Original Primary Outcome Measures (submitted: October 13, 2015)

• Maximum Tolerated Dose at optimal infusion time [ Time Frame: 8 months ]
  maximum tolerated dose at optimal infusion time
• Maximum plasma concentration (Cmax) of EDO-S101 [ Time Frame: 8 months ]
  maximum plasma concentration of EDO-S101 in stage 1
• Confirm recommended phase 2 dose (RP2D) [ Time Frame: 10 months from beginning of stage 2 ]
  In stage 2, confirm recommended phase 2 dose.
• Overall response rate [ Time Frame: 10 months from beginning stage 2 ]
  Determine overall response rate
• EDO-S101 Area under the curve (AUC) [ Time Frame: 8 months ]
  Determine EDO-S101 AUC in plasma

Current Secondary Outcome Measures (submitted: February 10, 2020)

• Time to objective response [ Time Frame: 10-20 months after beginning stage 2 ]
  Evaluate time to objective response by cohort
• Duration of response [ Time Frame: 10-20 months after beginning stage 2 ]
  Evaluate duration of response
• Progression free survival (PFS) [ Time Frame: 32-36 months after beginning stage 2 ]
  Determine time to progression free survival time for patients who received the RP2D
• Overall Survival (OS) [ Time Frame: 32-36 months after beginning stage 2 ]
  Determine the overall survival time for patients who received the RP2D
• Maximum Plasma Concentration (Cmax) [ Time Frame: 10-20 months after beginning stage 2 ]
  Determine Cmax using the PK population
• Time to Reach Maximum Concentration (Tmax) [ Time Frame: 10-20 months after beginning stage 2 ]
  Determine Tmax using the PK population
• Time taken for the plasma concentration to fall by half its original value (t1/2) [ Time Frame: 10-20 months after beginning stage 2 ]
  Determine t1/2 using the PK population
• Area Under Curve (AUC) [ Time Frame: 10-20 months after beginning stage 2 ]
  Determine area under the plasma drug concentration-time curve using the PK population
• QT (QTc) analysis [ Time Frame: 10-20 months after beginning stage 2 ]
  To perform a concentration corrected QT analysis
• Number of patients with treatment-emergent adverse events (TEAEs). TEAEs will be assessed by NCI-CTCAE 4.03 [ Time Frame: 10-20 months after beginning stage 2 ]
  Patient safety data will be summarized by disease cohort as well as overall disease cohorts pooled (i.e., MM, Hodgkin's lymphoma, non-Hodgkin's lymphoma, PTCL, T- PLL)

Original Secondary Outcome Measures (submitted: October 13, 2015)

• Progression free survival time [ Time Frame: 10 months after beginning stage 2 ]
  Determine the progression free survival time for patients who received the RP2D
• Overall survival [ Time Frame: 10 months after beginning stage 2 ]
  Determine overall survival time for patients who received the RP2D
• Maximum plasma concentration of EDO-S101 in patients receiving RP2D [ Time Frame: 10 months after beginning stage 2 ]
  Determine maximum plasma concentration of EDO-S101 in patients receiving the RP2D in stage 2

Current Other Pre-specified Outcome Measures (submitted: April 12, 2022)

Sub study cardiac safety [ Time Frame: 2 cycles ]

To characterize the effect of tinostamustine at a dose of 100 mg/m2 on cardiac repolarization (QTcF) and other ECG parameters

• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
• Official Title: A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
• Brief Summary: This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

Detailed Description

Tinostamustine is a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule. It is anticipated that tinostamustine may have activity in various hematological malignancies and solid tumors.

The study consists of 2 stages:

• Stage 1: Dose Escalation to determine Maximum Tolerated Dose (MTD) at the optimal infusion time and the pharmacokinetic (PK) profiles; is expected to enroll between 21 and 48 patients. Stage 1 has now been completed.
• Stage 2: Expansion in five Cohorts, in which approximately 12-16 patients will be enrolled per cohort, for a maximum of 70 patients.

In Stage 1, tinostamustine doses were escalated following the standard 3+3 design. The decision to escalate to the next dose level occurred after all cohort patients completed 3 weeks (21 days) of observation and have been evaluated for safety and toxicity.The starting dose was a 1 hour infusion of 20 mg/m2, and the maximum dose level was 150 mg/m2. Reduced infusion times of 45 minutes and 30 minutes were assessed once the maximum tolerated dose at a 1-hour infusion was determined.

In Stage 2, five cohorts of patients (with relapsed/refractory multiple myeloma (MM); relapsed/refractory Hodgkin's lymphoma; relapsed/refractory peripheral T-cell lymphoma (PTCL); relapsed/refractory cutaneous T-cell lymphoma (CTCL); and relapsed/refractory T-cell Prolymphocytic leukemia (T-PLL) will be enrolled and treated at the recommended Phase 2 dose (RP2D) based on results of Stage 1. For MM patients, treatment will occur on Day 1 and Day 15 of a 28 day cycle. For lymphoma patients, treatment will occur on Day 1 of a 21 day cycle. Patients in each stage of the study are expected to receive a median of four Cycles of therapy, and the maximum number of treatment Cycles allowed is 12.

A sub study portion was added to the protocol as an amendment. In the sub study 6 patients will be treated with 100mg/m2 tinostamustine infusion delivered over 100 minutes.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Hematological Malignancies
• Multiple Myeloma
• Hodgkin's Lymphoma
• Cutaneous T Cell Lymphoma

• Intervention: Drug: Tinostamustine

Study Arms

Experimental: Tinostamustine (EDO-S101)

EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2

Intervention: Drug: Tinostamustine

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: January 7, 2019): 111
• Original Estimated Enrollment (submitted: October 13, 2015): 84
• Estimated Study Completion Date: September 2023
• Estimated Primary Completion Date: May 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Patient willing and able to sign an informed consent.
2. Patients age ≥18 years at signing the informed consent.
3. Life expectancy > 3 months.
4. Diagnosis of relapsed or refractory lymphoid malignancy for which there are no available therapies.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2
6. Absolute Neutrophil Count >1,000 µL
7. Platelets ≥100,000 µL
8. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 upper limit of normal (ULN).
9. Total bilirubin <2.0 mg/dL unless elevated due to known Gilbert's syndrome.
10. Creatinine ≤1.5 x ULN.
11. Serum potassium and magnesium at least at the lowest limit of normal (LLN) at baseline(before every IMP administration; if it is below LNN, (supplementation is permissible).
12. Males and females of child-bearing potential, and their partners, must be willing to use at least two effective forms of birth control during the study drug administration and for at least 90 days after the administration of the study drug to be eligible to participate. Vasectomized partners and patients must be willing to use a secondary method of effective birth control. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.

Specific Eligibility Criteria for Each Patient Cohort in Stage 2 Phase of the Study

Cohort 1: relapsed/refractory multiple myeloma (Recruitment to this cohort stopped Dec 2021) 1. At least one line of prior systemic therapy and no other standard therapy available with proven clinical benefit.

Cohort 2: relapsed/refractory Hodgkin's lymphoma

1. At least two lines of prior therapy and no other standard therapy available with proven clinical benefit.

Cohort 3: PTCL (recruitment to this cohort stopped March 2021)

1. Only PTCL patients with histologically or cytologically confirmed Peripheral T-Cell Lymphoma - Not Otherwise Specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), or Anaplastic Large Cell Lymphoma (ALCL).
2. At least one line of prior combination therapy and no other standard therapy available with proven clinical benefit

Cohort 4: relapsed/refractory cutaneous T-cell lymphoma (CTCL), subtypes mycosis fungoides (MF) and Sézary syndrome (SS)

1. Only CTCL patients with histologically or cytologically confirmed MF or SS with stage IIb to IVb disease based on modified ISCL/EORTC staging.
2. At least one line and a maximum of four prior standard systemic therapies and no other standard therapy available with proven clinical benefit.

Cohort 5: PTCL (Recruitment to this cohort stopped March 2021)

Eligibility criteria for sub study:

Diagnosis of relapsed or refractory lymphoma, including Diffuse large B cell lymphoma who failed at least 2 lines of prior systemic therapy, Hodgkin lymphoma who failed at least 3 lines of prior systemic therapy, follicular lymphoma grade 1-3a, marginal zone lymphoma and mantle cell lymphoma who failed at least 2 lines of prior systemic lines of prior therapy, T cell lymphoma (including PTCL, CTCL) who failed at least 2 lines of prior systemic therapy for which there are no available therapies. Patients with bulky disease and Multiple Myeloma patients are excluded from this sub study.

Exclusion Criteria:

1. Patients with any central nervous system involvement.
2. Patient who had a hematologic malignancy that has transformed.
3. Any patient who has relapsed within 100 days of stem cell infusion following an allogenic or an autologous bone marrow transplant.
4. Patients with corrected QT (QTc) interval (Fridericia's formula) > 450 msec.
5. Patients who are on treatment with drugs known to prolong the QT/QTc interval.
6. Any serious medical condition that interferes with adherence to study procedures.
7. Patients with a history of another malignancy diagnosed within three years of study enrollment excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
8. Pregnant or breast feeding females.
9. New York Heart Association (NYHA) stage III/IV congestive heart failure. The following arrhythmias not adequately controlled, active: atrial fibrillation/flutter with poor rate control, documented sustained ventricular tachycardia (defined as >30 seconds or requiring cardioversion before 30 seconds have elapsed) or TdP.
10. Active infections, or other significant co-morbidities [(e.g., active central nervous system metastases and/or carcinomatous meningitis, active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C.
11. Previous cancer therapies within three (3) weeks of dosing as long as the patient has recovered to eligibility levels prior to treatment in this study.
12. Use of other investigational agents within 30 days or 5 half-lives prior to the first dose of study drug unless patient has recovered from any related toxicities ≥ Grade 1.
13. Steroid treatment within seven (7) days prior to study treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to 10 mg PO QD or less seven (7) days prior to study drug administration are allowed.
14. Patients on Valproic Acid for any indication (epilepsy, mood disorder) must be excluded from the trial .

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Listed Location Countries: France, Germany, Italy, Netherlands, Spain, Switzerland, United States

Administrative Information

• NCT Number: NCT02576496
• Other Study ID Numbers: EDO-S101-1001
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: relevant patient listing data of de-identified patients may be reviewed

• Current Responsible Party: Mundipharma Research Limited
• Original Responsible Party: Mundipharma-EDO GmbH
• Current Study Sponsor: Mundipharma Research Limited
• Original Study Sponsor: Mundipharma-EDO GmbH
• Collaborators: Not Provided

Investigators

• Principal Investigator: Pier L Zinzani, MD,PhD; University of Bologna Medical Center, Bologna

• PRS Account: Mundipharma Research Limited
• Verification Date: March 2023